UA102075C2 - Композиция и способы применения антител к склеростину - Google Patents

Композиция и способы применения антител к склеростину

Info

Publication number
UA102075C2
UA102075C2 UAA201003979A UAA201003979A UA102075C2 UA 102075 C2 UA102075 C2 UA 102075C2 UA A201003979 A UAA201003979 A UA A201003979A UA A201003979 A UAA201003979 A UA A201003979A UA 102075 C2 UA102075 C2 UA 102075C2
Authority
UA
Ukraine
Prior art keywords
compositions
methods
antibodies against
against sclerostin
sclerostin
Prior art date
Application number
UAA201003979A
Other languages
English (en)
Ukrainian (uk)
Inventor
Михаэла Кнейссел
Кристина Альо
Шоу-Их Ху
Беате Диефенбах-Штрейбер
Йозеф Прасслер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Priority claimed from PCT/EP2008/063691 external-priority patent/WO2009047356A1/en
Publication of UA102075C2 publication Critical patent/UA102075C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к антителу к склеростину, а также к фармацевтической композиции, которая содержит указанное антитело, и к способу применения указанного антитела для лечения заболевания, связанного с аномалиями в костной ткани, такими как остеопороз.
UAA201003979A 2007-10-12 2008-10-10 Композиция и способы применения антител к склеростину UA102075C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118414 2007-10-12
PCT/EP2008/063691 WO2009047356A1 (en) 2007-10-12 2008-10-10 Compositions and methods for use for antibodies against sclerostin

Publications (1)

Publication Number Publication Date
UA102075C2 true UA102075C2 (ru) 2013-06-10

Family

ID=39046845

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201003979A UA102075C2 (ru) 2007-10-12 2008-10-10 Композиция и способы применения антител к склеростину

Country Status (1)

Country Link
UA (1) UA102075C2 (ru)

Similar Documents

Publication Publication Date Title
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
WO2008025020A3 (en) Cd30 binding agents and uses thereof
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
IL195341A (en) A method of preparing simvastatin and compounds containing simvastatin
WO2008027739A3 (en) Antibodies to ntb-a
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
JO3313B1 (ar) التراكيب والطرق لزيادة نمو العضلة
TW200745003A (en) Novel compounds
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
MX2012004525A (es) Compuestos.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
UA102867C2 (ru) Антитела к cxcr4 и их применение в лечении рака
EA200970175A1 (ru) Способы и композиции для ингибирования ангиогенеза
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2009051957A3 (en) Antibodies to irem-1
EA201070893A1 (ru) Способы и композиции для лечения заболеваний костей
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.